Aspect Biosystems expands partnership with Novo Nordisk to develop diabetes treatment

Aspect Biosystems expands partnership with Novo Nordisk to develop diabetes treatment

Vancouver company’s 3-D live tissue-printing technology will incorporate key biological materials and receive new investment from Danish pharma giant

Novo Nordisk and Aspect Biosystems advance partnership for diabetes therapies

Novo Nordisk and Aspect Biosystems have started a new phase in their ongoing partnership focused on curative cellular medicines to treat diabetes.The post Novo Nordisk and Aspect Biosystems advance partnership for diabetes therapies appeared first on Hospital Management.

Aspect Biosystems and Novo Nordisk enter New Phase of Partnership to Develop Curative Medicines for Diabetes - Life Sciences British Columbia

Novo Nordisk and Aspect Biosystems announced a new phase of their partnership to develop advanced cellular medicines for diabetes.

Aspect Biosystems, Novo Nordisk Deepen Collaboration on Diabetes Cell Therapies

Vancouver-based Aspect Biosystems and Danish pharmaceutical giant Novo Nordisk are expanding their partnership to advance the development of next-generation cellular medicines aimed at treating diabetes. The companies said the new phase of their collaboration builds on work underway since 2023 and reflects a shared goal of accelerating potentially curative therapies for serious metabolic diseases. Under the updated agreement, Aspect has acquired…